Prothena Corporation plc
PRTA · NASDAQ
Market closed$8.66$0.190000 (+2.24%)After hours $8.66 · 0.00%
Key statistics
Previous close$8.47
Open$8.29
Day high$8.80
Day low$8.28
52-week high$11.80
52-week low$6.24
Market cap453.38M
Volume390.83K
Average volume547.03K
P/E ratio-3.53
Forward P/E—
EPS-2.45
Dividend yield0.00%
Market context
Why it moved
PRTA edged higher in light trading as general market momentum provided modest support, with no specific company-driven catalyst identified to account for the moderate uptick in share price.
What is happening
Recent company-specific developments and publisher coverage.
ad-hoc-news.de · July 7, 2026Prothena Corp plc updates investors on pipeline progress as neurodegeneration focus deepensThe Global Legal Post · June 19, 2026Biotech company Prothena promotes deputy GC to legal headTradingView · May 26, 2026Prothena 10% Owner Purchased Shares Worth Over $981KBusiness Wire · May 7, 2026Prothena Reports First Quarter 2026 Financial Results and Business HighlightsBusiness Wire · April 27, 2026Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with CardiomyopathyInvesting.com · April 10, 2026Prothena promotes Kingston, Isaacs to leadership rolesInvesting.com · March 24, 2026H.C. Wainwright reiterates Prothena stock rating on Parkinson’s dataBioSpace · August 28, 2025Prothena’s Alzheimer’s Drug Comes With Familiar Side Effect in Phase I Test Mt Newswire · June 5, 2026Prothena Corp Public Ltd Insider Bought Shares Worth $465,295, According to a Recent SEC Filing Mt Newswire · June 3, 2026Prothena Corp Public Ltd Insider Bought Shares Worth $471,300, According to a Recent SEC Filing Benzinga · May 26, 2026UPDATED: Watching Prothena; Shares Spike Higher, Form4 Filing Shows William P. Scully Bought 100,000 Shares At An Average Price Of $9.81/Share Mt Newswire · May 26, 2026Prothena Insider Bought Shares Worth $981,300, According to a Recent SEC Filing Benzinga · May 8, 2026Citizens Maintains Market Outperform on Prothena Corp, Raises Price Target to $20 Benzinga · May 7, 2026Prothena Corp Q1 EPS $0.60 Beats $(0.34) Estimate, Sales $51.084M Beat $1.010M Estimate Mt Newswire · April 27, 2026Prothena Says Novo Nordisk Gets FDA Fast Track Designation for Coramitug in ATTR-CM Benzinga · April 27, 2026Prothena Announces Coramitug Amyloid Depleter Antibody Receives FDA's Fast Track Designation To Treat ATTR Amyloidosis With Cardiomyopathy